Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

John Carroll

Editor & Founder

After months of market rumors and speculation, activist investor Elliott has begun its assault on CEO Emma Walmsley with a lengthy manifesto on the need …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Dutch biotech gets $146M for late-stage trials in three metabolic disorders

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

UnitedHealth Group CEO Andrew Witty steps down

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

Editor & Founder

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'